An interventional study of Single Port Robotic Surgery and Laser Surgery in Prostate Hyperplasia, sponsored by University of Illinois at Chicago. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 88 Years. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.
Among the 188 studies in Prostatic Hyperplasia with a site in United States, this one is the 64th largest by planned enrollment of the 150 interventional ones that give a count, is one of 11 that started in 2024, is one of 63 with no phase, reaches primary completion later than 17 of the 47 other live ones, and was the 160th registered.
831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.
Browse Prostatic Hyperplasia studies →29 of the 188 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:
ALPFA Medical · Sites in United States
Ages 45+ · Men only
ProVerum Medical · Sites in United States
Ages 45+ · Men only
Zenflow, Inc. · Sites in United States
Ages 18+ · Men only
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 88 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 28 · Phase 4 16
First in 1988; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 116 is above the median of 94 across 629 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 83 across the 150 interventional studies, 201 across the 37 observational. Of the 121 that completed or were terminated, 58 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 188 have an industry lead sponsor. The 10 most frequent:
University of Illinois at Chicago is the lead sponsor of 496 studies on the registry; 115 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
University of Illinois at Chicago has 2 studies filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
14 of the studies in Prostatic Hyperplasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04288427Beth Israel Deaconess Medical Center5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy | 2026-12-30 |
| NCT05400980Prodeon Medical, IncExpander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath | 2027-01 |
| NCT06224218University of Illinois at ChicagoProstate Single Port & Laser Enucleation Comparison Trial | 2027-01-15 |
| NCT06560476Urotronic Inc.OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH | 2027-03-30 |
| NCT05898932Northwestern UniversityEnhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes | 2027-04 |
Add all 14 to your calendar (.ics) → With an account.
Among the 188 studies in Prostatic Hyperplasia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Surgical treatments for benign prostatic hyperplasia (BPH) are necessary when non-procedural approaches fail to alleviate lower urinary tract symptoms (LUTS) or bladder outlet obstruction (BOO). Open simple prostatectomy and laser enucleation are recommended for prostatic adenoma size greater than 80 ml. Minimally invasive approaches, such as robotic-assisted simple prostatectomy, have gained popularity due to their comparable outcomes with lower morbidity. The introduction of the da Vinci single-port (SP) robotic platform offers potential advantages, but its outcomes have not been thoroughly investigated.
This randomized controlled trial aims to compare the outcomes of SP simple prostatectomy performed using the da Vinci robotic platform versus thulium laser enucleation of the prostate for the treatment of BPH and BOO.
Patients diagnosed with symptomatic BPH and eligible for surgical intervention will be randomized to undergo either SP robotic simple prostatectomy or thulium laser enucleation of the prostate. Primary outcomes will include perioperative parameters (operative time, estimated blood loss, hospital stay), postoperative complications, and functional outcomes (urinary symptoms, urinary flow rate). Secondary outcomes will evaluate perioperative and postoperative complications, oncologic outcomes, and patient-reported quality of life measures.
In a recent retrospective study at UI Health from 2017 to 2021, investigators compared 103 procedures, SP robotic prostatectomy versus laser enucleation, 34 SP robotic prostatectomy and 69 laser enucleations. There was no difference in any complication at 30-day post-surgery (21.2% vs. 21.7%, p=0.9517). Investigators recognize SP robotic surgery leads to longer operating times, due to docking the instrument and closing the incision, as well as longer catheter times to allow the cystostomy to heal. While the laser enucleation may be considered less invasive, as no incision is required, the instrumentation of the urethra could lead to urethral strictures. This study aims to provide valuable insights into the clinical outcomes of single port simple prostatectomy using SP robotic platform, compared to laser enucleation of the prostate prospectively. The results of this trial will help guide clinicians and patients in selecting the most appropriate surgical intervention for symptomatic BPH, considering both functional outcomes and morbidity. Both procedures are currently performed at UI Health, they are FDA approved, therefore this is not a safety study. Subject insurance will not impact which subject will receive one procedure or the other, as both procedures are recommended on the American Urological Association guidelines for Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia.
The study will be a randomized controlled trial comparing SP simple prostatectomy vs laser enucleation of the prostate. The study findings will improve clinical decision-making and aid in optimizing patient outcomes in the management of BPH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Removal of the prostate using single port robot
Procedure: Single Port Robotic Surgery
Enucleation of the prostate with laser surgery
Procedure: Laser Surgery
Single port Robotic surgery will remove the whole prostate
Laser enucleation will remove chips of the prostate but keeping intact the prostate capsule.
Operative time
Time in minutes from the start to finish of the procedure.
Time frame: During procedure
International Consultation of Incontinence Questionnaire Short Form
How often do you leak urine? never 0 about once a week 1 two or three times a week 2 about once a day 3 several times a day 4 all the time 5 How much urine do you usually leak (whether you wear protection or not)? none 0 a small amount 2 a moderate amount 4 a large amount 6 Overall, how much does leaking urine interfere with your everyday life? 0 (not at all) and 10 (a great deal) 0 1 2 3 4 5 6 7 8 9 10 ICIQ score: sum previous questions. When does urine leak? never - urine does not leak before you can get to the toilet when you cough or sneeze when you are asleep when you are physically active/exercising when you have finished urinating and are dressed for no obvious reason all the time
Time frame: Before procedure and 7 months after procedure
Sexual Health Inventory for Men (SHIM)
1. How do you rate your confidence to keep an erection? 1 Very low 2 3 4 5 Very high 2. How often were your erections hard enough for penetration? 1 Almost never 2 3 4 5Almost always 3. How often were you able to maintain your erection after you had penetrated your partner? 1Almost never 2 3 4 5Almost always 4. How difficult was it to maintain your erection to completion of intercourse? 1Extremely difficult 2 3 4 5Not difficult 5. When you attempted sexual intercourse, how often was it satisfactory for you? 1Almost never 2 3 4 5Almost always Add together the numbers. If the patient's score is 21 or less, erectile dysfunction (ED) should be addressed. 22 - 25: No significant erectile dysfunction 17 - 21: Mild erectile dysfunction 12 - 16: Mild-to-moderate erectile dysfunction 8 - 11: Moderate erectile dysfunction 5 - 7: Severe erectile dysfunction
Time frame: Before procedure and 7 months after procedure
International Prostate Symptom Score I-PSS
1. How often have you had a sensation of not emptying your bladder completely after you finish urinating? 0= not all 1. less than 1 time in 5 2. less than half the time 3. about half the time 4. more than half the time 5. almost always 2. How often have you had to urinate again less than two hours after you have finished urinating? 0 1 2 3 4 5 3. How often have you found you stopped and started again several times when you urinated? 0 1 2 3 4 5 4. How often have you found it difficult to postpone urination? 0 1 2 3 4 5 5. How often have you had a weak urinary stream? 0 1 2 3 4 5 6. How often have you had to push or strain to begin urination? 0 1 2 3 4 5 7. How many times did you most typically get up each night to urinate from the time you went to bed until the time you got up in the morning? 0 1 2 3 4 5 Sum previous questions to have the score: 0 - 7 = mildly symptomatic; 8 - 19 = moderately 20 - 35 = severely
Time frame: Before procedure and 7 months after procedure
Urinary flow rate
Measure of the urine flow in mL/s
Time frame: Before procedure and 7 months after procedure
Post void residual volume
Amount of urine retained in the bladder after a voluntary void measure with Ultrasound. Volume = length x width x height x 0.52
Time frame: Before procedure and 7 months after procedure
Blood loss during procedure
Estimate blood loss in mL during procedure
Time frame: During procedure
Hospital stay after procedure
Amount of time spent at the hospital after procedure measure in hours
Time frame: From end of procedure to discharge home (up to 30 days )
Number of subjects with injuries related to surgical procedures.
Descriptive report of complications during surgery.
Time frame: During procedure
Quality of life due to urinary symptoms
If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that? 0 1 2 3 4 5 6 0= delighted 1. please 2. mostly satisfied 3. mixed 4. mostly unhappy 5. unhappy 6. terrible
Time frame: Before procedure and 7 months after procedure
Number of subjects with incidental cancer
Pathology report of prostate tissue, presence or absence of prostate cancer.
Time frame: 2 weeks after procedure
Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 36 months after the start.
Of 155 non-industry interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's planned 36 months is above that.
Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Illinois at Chicago →